Featured Breakthroughs & Updates
Radiodiagnostic
News
CytoSite Bio Announces Agreement with Lantheus for Granzyme B Targeted PET Imaging Radiotracer for Immunotherapy Assessment
March 26, 2025
Radiodiagnostic
Press Release
Cytosite Bio Launches Granzyme B Targeted PET Imaging Biopharmaceutical Services Program for Immunotherapy Assessment of Patient in Clinical Trials
March 29, 2029
Radiotherapeutic
News
CytoSite Bio Presents First-in-Human Data at Radiological Society of North American Annual Meeting
October 15, 2025
Radiodiagnostic
News
Granzyme B PET Imaging for Assessment of Disease Activity in Inflammatory Bowel Disease
October 15, 2025
Granzyme B
News
Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy response
October 15, 2025
Radiotherapeutic
Press Releases
FDA Grants Orphan Drug Designation for Lead Candidate
October 16, 2025
Radiodiagnostic
Press Releases
FDA Grants Orphan Drug Designation for Lead Candidate
October 16, 2025
Radiotherapeutic
Press Releases
FDA Grants Orphan Drug Designation for Lead Candidate
October 16, 2025
Scientific Articles
view all
Immunotherapy
Scientific Articles
5 Key Challenges in Developing Cancer Immunotherapies
October 16, 2025
Radiotherapeutic
Scientific Articles
Understanding the Role of CDK7 in Tumour Growth
October 16, 2025
Partner with us
Could Your Pipeline Benefit from a 1-2 Week Go or No-Go Decision?
Validated therapeutic efficacy with 95% accuracy across 5 cancer types—where advanced diagnostics meets targeted radiopharmaceuticals.